Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEMS2 fetal neural stem cell transplantation in progressive multiple sclerosis
2024-511028-15-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tacrolimus in multiple sclerosis (MS) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Change in whole brain volume. Planned start Aug 2025; status: authorised.
02
Drugs
tacrolimus
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-511028-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511028-15-00.